Discovery is in our nature
Introducing a new generation of psychedelic-inspired medicines
We have created a vast library of patentable and highly active new chemical entities (NCEs) that are designed to target serotonin receptors in a specific manner to enable the treatment of multiple neurological diseases and disorders.
PsiloSterics | Who We Are
Moving beyond the First-Gen approach
First-generation psychedelic companies are largely focused on “repackaging” old drugs that were initially discovered by scientists more than 30 years ago, resulting in many companies pursuing the advancement of known hallucinogenic drugs that require the presence of a medical professional when administered to patients.
Our next-gen approach: Pseudo-psychedelic therapeutics
We have designed and synthesized novel, non-hallucinogenic serotonin receptor agonists that reduce or eliminate the cardiotoxic effects commonly observed with known hallucinogenic drugs, allowing for long-term, unsupervised administration to patients on a daily or weekly basis. This design approach has guided us to over a dozen proprietary, patent-pending molecular scaffolds covering thousands of novel therapeutic compounds that can be tailored to target a variety of neurological disorders.
Collaborating with some of the top academic groups in the industry, our top NCE candidates are being advanced through a battery of in vitro and in vivo pre-clinical studies to enable lead candidate selection and optimization.
a New Generation of psychedelic inspired medicines
Our Process
Design
By combining proprietary SAR analytics, medicinal chemistry analyses, and exhaustive prior art research, we design and synthesize novel molecular scaffolds.
Selection
Using in silico screening and molecular modeling, we narrow our focus to refine and select scaffolds with the highest likelihood of replicating – or exceeding – the therapeutic benefits of traditional psychedelic compounds, while reducing or eliminating the hallucinogenic and cardiotoxic aspects of those drugs.
Patent Filing
We rigorously examine the IP landscape to determine patentability and freedom to operate for our novel scaffolds and their related NCE candidates. So far, this has resulted in the preparation and filing of more than 30 patent applications, with many of those applications individually disclosing 500+ novel compounds.
NCE synthesis
Leveraging our in-house laboratory and 50+ years of combined medicinal chemistry expertise, we synthesize, prepare and characterize our NCEs for in vitro and in vivo studies.
pre-clinical studies
Once identified as a potential lead, our top NCE candidates are advanced into our pre-clinical program with leading academic collaborators for optimization and indication-specific studies.
The Opportunity Ahead
Psychedelic drugs have the potential to address multiple indications affecting large population groups that make up extremely sizable markets. However, many First-Gen natural and synthetic analogs are not optimized for continual therapeutic use. Our novel therapeutics are designed without the hallucinogenic and other side effects that have prevented existing psychedelics from being widely adopted for addressing the current global epidemic of mental health disorders.
Unlike naturally-occurring or synthetic serotonergic agents previously developed, our new generation of NCEs are novel and patentable, allowing us to avoid the vast and complicated IP landscape created by First-Gen companies. PsiloSterics exclusively owns all intellectual property rights associated with its proprietary scaffolds and NCEs.
Our Team
Our Partners
